Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids
Bioorganic & Medicinal Chemistry, ISSN: 0968-0896, Vol: 26, Issue: 9, Page: 2271-2279
2018
- 22Citations
- 53Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations22
- Citation Indexes21
- 21
- CrossRef11
- Patent Family Citations1
- Patent Families1
- Captures53
- Readers53
- 53
Article Description
Natural products have been used for many medicinal purposes for centuries. Antibody drug conjugates (ADCs) have utilized this rich source of small molecule therapeutics to produce several clinically useful treatments. ADCs based on the natural product maytansine have been successful clinically. The authors further the utility of the anti-cancer natural product maytansine by developing efficacious payloads and linker-payloads for conjugating to antibodies. The success of our approach was realized in the EGFRvIII targeting ADC EGFRvIII-16. The ADC was able to regress tumors in 2 tumor models (U251/EGFRvIII and MMT/EGFRvIII). When compared to a positive control ADC, the efficacy observed was similar or improved while the isotype control ADCs had no effect.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0968089617321090; http://dx.doi.org/10.1016/j.bmc.2018.02.025; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85044541621&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/29605304; https://linkinghub.elsevier.com/retrieve/pii/S0968089617321090; https://dx.doi.org/10.1016/j.bmc.2018.02.025
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know